These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17646593)

  • 21. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
    Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
    J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination stroke therapy: easy as APC?
    Lo EH
    Nat Med; 2004 Dec; 10(12):1295-6. PubMed ID: 15580249
    [No Abstract]   [Full Text] [Related]  

  • 23. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
    Mendioroz M; Fernández-Cadenas I; Alvarez-Sabín J; Rosell A; Quiroga D; Cuadrado E; Delgado P; Rubiera M; Ribó M; Molina C; Montaner J
    Cerebrovasc Dis; 2009; 28(2):143-50. PubMed ID: 19546541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
    Dai Q; Sun W; Liu X
    Stroke; 2014 Jul; 45(7):e132. PubMed ID: 24916904
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue plasminogen activator in Israel: are we there yet?
    Ben-Hur T; Leker RR
    Isr Med Assoc J; 2009 Dec; 11(12):749-50. PubMed ID: 20166343
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy.
    Toni D; Lorenzano S; Agnelli G; Guidetti D; Orlandi G; Semplicini A; Toso V; Caso V; Malferrari G; Fanucchi S; Bartolomei L; Prencipe M
    Cerebrovasc Dis; 2008; 25(1-2):129-35. PubMed ID: 18073466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
    Whiteley WN; Thompson D; Sandercock P
    Stroke; 2014 Jul; 45(7):e133. PubMed ID: 24916910
    [No Abstract]   [Full Text] [Related]  

  • 28. Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
    Hsieh HC; Chen CH
    Clin Neurol Neurosurg; 2009 Jul; 111(6):562-3. PubMed ID: 19200644
    [No Abstract]   [Full Text] [Related]  

  • 29. Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.
    Liang BA; Zivin JA
    Ann Emerg Med; 2008 Aug; 52(2):160-4. PubMed ID: 18313798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taming the clot-buster tPA.
    Dawson TM; Dawson VL
    Nat Med; 2006 Sep; 12(9):993-4. PubMed ID: 16960567
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteplase beyond three hours in ischemic stroke: do we know enough?
    Jawaid A; Fitch O; Qureshi S; Wilson AM; Schulz PE
    Int J Stroke; 2009 Apr; 4(2):70. PubMed ID: 19383044
    [No Abstract]   [Full Text] [Related]  

  • 33. Frontiers in research series: Stroke. Introduction.
    Ying W; Su DF
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):236-7. PubMed ID: 19769602
    [No Abstract]   [Full Text] [Related]  

  • 34. [Orolingual angioedema secondary to alteplase treatment in cases of stroke].
    Giménez-Muñoz A; Capablo-Liesa JL; Torné-Hernández L; Sagarra-Mur D; Sebastián-Torres B; Alarcia-Alejos R
    Rev Neurol; 2008 Mar 16-31; 46(6):382. PubMed ID: 18368687
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue plasminogen activator for stroke and concomitant influenza infection: is this a dangerous combination?
    Grau AJ
    Stroke; 2011 Mar; 42(3):585-6. PubMed ID: 21293013
    [No Abstract]   [Full Text] [Related]  

  • 37. Recanalization and reperfusion therapies for acute ischemic stroke.
    Molina CA; Alvarez-Sabín J
    Cerebrovasc Dis; 2009; 27 Suppl 1():162-7. PubMed ID: 19342847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telemedicine is crucial to implementing acute stroke therapy.
    Savitz SI
    MedGenMed; 2006 Feb; 8(1):39. PubMed ID: 16915169
    [No Abstract]   [Full Text] [Related]  

  • 39. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Past, present and future of alteplase for acute ischemic stroke.
    Quinn TJ; Dawson J; Lees KR
    Expert Rev Neurother; 2008 Feb; 8(2):181-92. PubMed ID: 18271705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.